Atara Biotherapeutics Inc. Registered Shares New DL-,0001
- BID
7.15
- ASK
7.3
- 420 Units420 Units
- 07/21, 17:30:43 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
-
Market Cap
66.77 Mil.
P/E Ratio
7.04
Dividend Yield
0.00 %
Earnings per Share
2.28 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 7.15 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 05:18:46 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 7.25 | 7.15 |
| PREV. DAY'S PRICE | 7.2 | (07/20) |
| CHANGE DAY BEFORE | -0.05 | -0.69 % |
| 52 WEEK HIGH / LOW | (-) | (-) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -60.29 | -10.54 | 2.28 | -1.13 | 0.78 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | 7.04 | - | 9.37 |
PRICE - BOOK RATIO | - | - | - | - | - |
PRICE - SALES RATIO | 6.34 | 0.77 | 1.90 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A40DQJ |
| ISIN | US0465132068 |
| SYMBOL | AT20 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ATARA BIOTH. NEW DL-,0001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 129.20 Mil. |
| MARKET CAPITALISATION | 66.77 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -14.79 % | -15.79 % | 71.43 % | - | - | -83.92 % | -97.41 % | - |
| HIGH | 7.60 | 10.20 | 10.20 | 10.20 | - | 241.44 | 421.50 | 10.20 |
| LOW | 6.90 | 6.90 | 3.70 | 3.36 | - | 3.36 | 3.36 | 3.36 |
Dividende
pro Aktie
ATARA BIOTH. NEW DL-,0001 does not deliver dividend information
Company profile
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.